Key clinical point: Response rates were high without dose limiting toxicities for propranolol added to pembrolizumab in treatment-naive metastatic melanoma, providing a basis for further study.
Major finding: Complete or partial responses were observed in 78% of patients with antitumor activity in all patients receiving 30 mg b.i.d.
Study details: The phase 1 study comprised nine patients receiving 10, 20, or 30 mg of propranolol b.i.d. added to 200 mg of pembrolizumab every 3 weeks.
Disclosures: The study was funded by Roswell Park, private, and NIH grants. The authors had no disclosures.
Gandhi S et al. Clin Cancer Res. 2020 Oct 30. doi: 10.1158/1078-0432.CCR-20-2381.